2023
Development of REDCap-based architecture for a clinical decision support tool linked to the electronic health record for assessment of medication appropriateness
Charpentier P, Mecca M, Brandt C, Fried T. Development of REDCap-based architecture for a clinical decision support tool linked to the electronic health record for assessment of medication appropriateness. JAMIA Open 2023, 6: ooad041. PMID: 37333904, PMCID: PMC10276359, DOI: 10.1093/jamiaopen/ooad041.Peer-Reviewed Original Research
2019
Medication Appropriateness in Vulnerable Older Adults: Healthy Skepticism of Appropriate Polypharmacy
Fried TR, Mecca MC. Medication Appropriateness in Vulnerable Older Adults: Healthy Skepticism of Appropriate Polypharmacy. Journal Of The American Geriatrics Society 2019, 67: 1123-1127. PMID: 30697698, PMCID: PMC6561813, DOI: 10.1111/jgs.15798.Peer-Reviewed Original ResearchConceptsNumber of medicationsAppropriate polypharmacyOlder adultsMedication benefitsComplex medication regimensMultiple chronic conditionsVulnerable older adultsMedication appropriatenessUnderestimate harmsInappropriate medicationsMore medicationsAdverse eventsMore observational studiesMedication regimensComplex regimenAdverse outcomesAppropriate medicationChronic conditionsMedications resultsObservational studyPolypharmacyMedicationsHealth outcomesCorrect medicationLikelihood of harm
2011
Effects of Benefits and Harms on Older Persons' Willingness to Take Medication for Primary Cardiovascular Prevention
Fried TR, Tinetti ME, Towle V, O’Leary J, Iannone L. Effects of Benefits and Harms on Older Persons' Willingness to Take Medication for Primary Cardiovascular Prevention. JAMA Internal Medicine 2011, 171: 923-928. PMID: 21357797, PMCID: PMC3101287, DOI: 10.1001/archinternmed.2011.32.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAspirinCardiotonic AgentsCardiovascular DiseasesDrug-Related Side Effects and Adverse ReactionsFemaleHealth Knowledge, Attitudes, PracticeHumansInterviews as TopicMaleMyocardial InfarctionPatient CompliancePatient ParticipationPatient SelectionPharmaceutical PreparationsPrimary PreventionRisk AssessmentSurveys and QuestionnairesConceptsPrimary cardiovascular disease preventionCardiovascular disease preventionMyocardial infarctionAbsolute benefitAdverse effectsDisease preventionOlder personsCommunity-living older personsPrimary cardiovascular preventionEvidence-based guidelinesAverage risk reductionRisk reductionCardiovascular preventionAvailable medicationsPrimary preventionClinical guidelinesTreatment benefitMild fatigueMedicationsQuality assurance initiativesPerson interviewsPreventionParticipantsHarmLarge proportion